It's a great pleasure to welcome you all in this, my first meeting
as Chairman of Anuh Pharma Ltd.
Anuh Pharma Ltd founded in 1960 began production of Active
Pharmaceuticals in 1989 at Boisar Maharashtra, specializing in manufacturing of metallic
stearates and antibiotics, with a 150-ton production capacity. Currently, Anuh Pharma Ltd
with capacity of 1800 tons ranks among the world's biggest producers of first-generation
erythromycin salts and is a leading producer of corticosteroids, anti-TB, anti-malarial,
and anti-diabetic products as well with Regulatory approvals from USFDA, EU and WHO Geneva
prequalification.
Today, the world and especially the pharma industry is facing several
challenges in terms of inflation, geopolitics, and supply chain disruptions. We need to
act quickly to keep abreast of the challenges confronting the industry. Efforts will be
required for thoughtful prioritization and we need to develop a more strategic, long-term,
and integrated approach to our operations.
The global economy has shown remarkable resilience in the face of grim
predictions, with steady growth and inflation slowing almost as swiftly as it soared. The
world growth rate is expected to remain stable at 3.2 percent this year and next, while
India's growth rate is anticipated to be between 6.5% and 7.5%, according to the most
recent World Economic Outlook predictions. # Source International Monetary Fund.
Despite the challenging global economic landscape, we have remained
resilient, adaptable, and focused on our strategic objectives. This steadfast dedication
has enabled us to navigate through uncertainties and emerge even stronger.
According to estimates, the size of the global market for active
pharmaceutical ingredients will be USD 252.34 billion in 2024, and it is projected to
increase at a compound annual growth rate (CAGR) of 5.75% between 2024 and 2030. The
biopharmaceutical industry's expansion, the aging population, and improvements in API
manufacturing are some of the major factors propelling the API market. It is projected
that a rise in the prevalence of chronic illnesses including cancer and cardiovascular
disease will accelerate market expansion.
#source grandviewresearch.com
The market for active pharmaceutical ingredients in India was valued at
USD 19.83 billion in 2023 and is projected to expand at a compound annual growth rate
(CAGR) of 7.7% between 2024 and 2030. The market has grown significantly as a result of
the growing number of elderly people, the growing burden of chronic illnesses, and the
ongoing need for affordable drugs.
Anuh Pharma Ltd is experiencing incredible progress in its path.
Average growth over the last five years has been 16%, and average growth over the next
five years is estimated to be higher than 15%, which is beating average industry rate of
7.7%. Anuh Pharma Ltd. reported revenue growth of 23.52% for FY24, going from 53,360 lakhs
to 65,910 lakhs. However, profit before tax increased by 64.97% from 4,747 lakhs to 7,831
lakhs. Earnings per share increased to Rs 11.98 from Rs 7.22 in the previous year. The
increase in earnings has also led to a rise in return on capital employed, which was
19.85% in FY23 and 26.82% in FY24.
Anuh Pharma plans to raise its manufacturing capacity at its Boisar
plant from 1800 MT to 2200 MT this year by investing Rs 20 crore in capital expenditure.
Company plans to launch five new products this year, mostly in the diabetic,
cardiovascular, and antibacterial categories, with an emphasis on research and
development. Its market share in the anti-malarial, corticosteroids, and anti-diabetic
medication categories is also anticipated to expand significantly. With regulatory
clearances such as the USFDA,
EU, and WHO Geneva prequalification, Anuh Pharma Ltd. is anticipated to
expand its market share for both new and current products. The company's net margin is
anticipated to rise in tandem with its increased market share in regulatory markets.
The company is also investing in alternative energy sources, such as
solar energy, to assist bringing about cost efficiency as it works toward reaching its
objective of lowering carbon emissions. Anuh Pharma Ltd. is committed to environmental
compliance, as seen by its zero liquid discharge facility, water conservation efforts, and
solvent recycling during the manufacturing process. The company is committed to
sustainable growth with focus on Quality & Research.
One of the pillars of our business culture continues to be Corporate
Social Responsibility (CSR). We have increased the scope of our efforts this year
especially in field of providing healthcare facility by providing medical equipments to
various private and government hospitals, also facilitating education to the needy ones,
providing hygiene facilities and food grains and other essentials to kidney patients. Our
dedication is in creating a culture of accountability and honesty while also having a
beneficial influence and building a better future for our stakeholders around the area of
our manufacturing plant at Boisar.
As we forge ahead, we recognize that the business landscape is evolving
rapidly. Technological advancements, shifting consumer preferences, and geopolitical
changes present both challenges and opportunities. However, I am confident that with our
robust business model, resilient infrastructure, and dedicated team, we are well-prepared
to navigate the future successfully. Our unwavering commitment to innovation, customer
satisfaction, and shareholder value will remain at the forefront of our strategic
priorities.
We firmly believe that our success is intrinsically linked to the
success of all our stakeholders. We remain deeply committed to creating shared value and
fostering long-term relationships with our valued customers, dedicated employees,
supportive communities, and our esteemed shareholders. Anuh Pharma will continue to
prioritize the interests of all stakeholders, seeking to exceed expectations and
contribute positively to society.
As always, my sincere gratitude to all shareholders, fellow directors,
management, and those concerned in the industry for their continued faith and trust in
Anuh Pharma. Rest assured, we will remain steadfast in our pursuit of excellence,
continuously striving to exceed expectations and deliver sustainable growth.
Best wishes and warmest regards to all of you and your families.
Thankyou